A decade later, I still remember standing in the kitchen on a phone call that would change my life. On that morning in March 2016, I left my apartment and returned nearly two weeks later with a pulmonary hypertension (PH) diagnosis. I never thought I’d reach this milestone: living…
Measuring levels of tiny pieces of genetic material in the blood, known as microRNAs, may help identify group 2 pulmonary hypertension (PH), according to a new study. “We identified a set of circulating [microRNAs] that are differentially expressed in Group 2 PH and correlated with disease severity,” researchers wrote…
A study found that a naturally occurring signaling molecule called C-type natriuretic peptide (CNP) reduced the severity of pulmonary arterial hypertension (PAH) in mice. “This study highlights the important role of [CNP] signaling in the [disease development] of PAH and suggests that modulation of this pathway may provide a…
Cereno Scientific has been cleared to launch a Phase 1 clinical trial in Sweden to evaluate the pharmacological properties of CS014, its experimental oral treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The upcoming study in healthy volunteers was designed based on feedback from the U.S.
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Get regular updates to your inbox.
